← All trials
NCT04486430
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 2, 2017
- Primary completion
- Jun 12, 2019
- Completion date
- Dec 13, 2019
- First posted
- Jul 24, 2020
- Last posted
- Jul 24, 2020
- Enrollment
- 236
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Peking UniversityCollaborator
- Soochow UniversityCollaborator
- Zhejiang UniversityCollaborator
- Central South UniversityCollaborator
- Hebei UniversityCollaborator
- Jilin UniversityCollaborator
- Jinan UniversityCollaborator
- Ningxia Medical UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Southern Medical UniversityCollaborator
- Shandong UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Capital Medical UniversityReponsible party - principal investigator
- Fudan UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- China Medical UniversityCollaborator
- Shandong Provincial HospitalCollaborator
- The Central Hospital of Lishui CityCollaborator
- Baotou Medical UniversityCollaborator
- Subei People's Hospital of Jiangsu ProvinceCollaborator
- Wenzhou Medical UniversityCollaborator
- Daqing Oil Field HospitalCollaborator
- Apeloa Pharmaceutical Co. Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.